Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ixico Plc LSE:IXI London Ordinary Share GB00BFXR4C20 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.50 -0.53% 94.50 32,059 09:57:57
Bid Price Offer Price High Price Low Price Open Price
93.00 96.00 95.00 94.50 95.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 7.56 0.37 0.92 102.7 45
Last Trade Time Trade Type Trade Size Trade Price Currency
12:53:01 O 971 94.055 GBX

Ixico (IXI) Latest News

More Ixico News
Ixico Investors    Ixico Takeover Rumours

Ixico (IXI) Discussions and Chat

Ixico Forums and Chat

Date Time Title Posts
08/10/202016:18Ixico PLC214
30/9/202012:22IXICO179

Add a New Thread

Ixico (IXI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
11:53:0294.06971913.27O
11:44:4695.9710,0009,597.00O
09:34:4195.9710095.97O
09:34:3595.973,1252,999.06O
09:23:4995.712,0131,926.72O
View all Ixico trades in real-time

Ixico (IXI) Top Chat Posts

DateSubject
20/10/2020
09:20
Ixico Daily Update: Ixico Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IXI. The last closing price for Ixico was 95p.
Ixico Plc has a 4 week average price of 83p and a 12 week average price of 63p.
The 1 year high share price is 96p while the 1 year low share price is currently 42p.
There are currently 47,091,292 shares in issue and the average daily traded volume is 102,287 shares. The market capitalisation of Ixico Plc is £44,501,270.94.
29/9/2020
07:25
donald pond: I assume they mean due to rather than coming. Bit amateurish but I think this is a solid buy and hold company. I imagine its share price will always be lumpy, hanging around one price band for ages then jumping to the next level and staying there etc, but its hard to not see it growing over time.
26/8/2020
14:45
deltaham: Uptick in share price will be due to RNS at 1.55am today from Ixico on yesterday's Investor presentation "IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that a recording of the online Company presentation, delivered by Giulio Cerroni, Chief Executive Officer, and Grant Nash, Chief Finance Officer, on Tuesday 25 August, surrounding the Company's recent trading update, is now available to watch back on the Investor Meet Company platform. The Q&A has also been published following the meeting. "Investors can sign up to Investor Meet Company for free and add to meet IXICO plc via the following link, which will take you to the recording of the presentation and the Q&A: hxxps://www.investormeetcompany.com/ixico-plc/register-investor No new price-sensitive information is disclosed as part of the presentation."
06/7/2020
07:04
shanklin: Very impressed to see share options that are not management stealing shares from shareholders. Both peformance conditions and options priced at the current share price rather than at 0p. Excellent, I hope the conditions are met for all 450k of them to be issued.
16/3/2020
13:59
jpuff: IXICO plc IXICO announces expanded contract with VaccinexSource: RNS Non-RegulatoryTIDMIXIIXICO plc16 March 202016 March 2020IXICO plc("IXICO" or the "Company")IXICO announces an expanded contract for its imaging services with VaccinexSupports Vaccinex's diversification into clinical development of pepinemab for Alzheimer's diseaseIXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces an award of a contract to provide imaging services for Vaccinex Inc.'s (Nasdaq: VCNX) planned Phase Ib/IIa trial of pepinemab, a potential treatment of Alzheimer's disease (AD). This will build on the Company's existing contract to support Vaccinex's Phase II study of pepinemab in the Huntington's disease SIGNAL trial, which was previously announced in September 2017.Giulio Cerroni, Chief Executive Officer of IXICO, commented:"This AD trial, called SIGNAL - AD, is part of a new wave of investment in treatments for neurodegeneration by the global biopharmaceutical industry, with additional assets being brought through the pipeline thanks to the insights unlocked in earlier research programmes."We are delighted that Vaccinex has chosen to expand our partnership to support its diversification into Alzheimer's disease. Our existing project with Vaccinex, the SIGNAL trial, is in Huntington's disease (HD) to study the safety and efficacy of pepinemab, where the positive imaging results obtained in an interim cohort analysis indicated its potential in additional therapeutic areas; this contract was initiated in 2017 and the new award is a great testament to the achievements of our two organisations working diligently together since then. We are pleased to be part of Vaccinex's effort to bring hope to AD patients and their families."This contract does not have significant impact on management's expectations of perfomance for the year.For further information please contact: IXICO plc +44 (0) 20 3763 7498 Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer Optimum Strategic Communications +44 (0) 203 950 9144 Mary Clark, Supriya Mathur, Manel Mateus IXICO@optimumcomms.com About IXICOIXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.More information is available on www.IXICO.comAbout Vaccinex, Inc.Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in non-small cell lung cancer and Huntington's disease. Vaccinex is based in Rochester, New York.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDNRABSGDXIXBDGGX(END) Dow Jones NewswiresMarch 16, 2020 05:00 ET (09:00 GMT)
17/2/2020
15:45
martinthebrave: Simon Thompson 12th December 2019 - "BUY" Annual results from Aim-traded IXICO (IXI:68p), a London-based company that uses proprietary artificial intelligence (AI) software algorithms to analyse images from brain scans were materially better than I had anticipated when I recommended buying the shares, at 33p, in the summer ('Alpha Report: Simon Thompson spies opportunity in cutting edge technology', 23 July 2019). Having upgraded his earnings forecasts twice since then, analyst Chris Donnellan at house broker Cenkos Securities has done so again on the back of the latest results, highlighting the ongoing strong momentum in the business. The scans – magnetic resonance imaging (MRI) and positron emission tomography (PET) – provide measurements of small changes in brain structure, assess the efficacy of new drugs being trialled, monitor patient safety, and provide valuable insights on different aspects of trial performance. Outsourcing the work to clinical research organisations is proving popular with the world’s largest biopharmaceutical companies that are investing huge sums of money in the field of neurology to target therapies for diseases affecting the central nervous system including Huntington’s, Alzheimer’s and Parkinson’s disease. IXICO reported record annual revenue of £7.6m, up 40 per cent year-on-year, and it’s high value work as gross margins were 6.6 percentage points higher at 65.4 per cent. This meant that gross profit, up 55 per cent to £5m, increased at a faster rate than revenue. So, with a relatively fixed cost base – operating expenses only increased by 14 per cent – IXICO has passed the inflexion point whereby an increasing proportion of gross margin earned from incremental revenue is converted into profit. To put the operational gearing of the business into perspective, IXICO’s operating loss of £0.8m on revenue of £5.4m in 2018 turned into an operating profit of £364,000 on revenue of £7.6m in the 12 months to 30 September 2019. Cenkos had predicted a maiden operating profit of £50,000, so this was a major earnings beat. Moreover, because gross margins are higher than Cenkos had anticipated, and operating costs lower, the broking firm has been forced to upgrade its operating profit estimates by a thumping 70 per cent to £508,000 for the 2019/20 financial year, and by 10 per cent to £1.04m the year after. Forecasts are based on annual revenue rising by 20 per cent to £9m and £10.8m, respectively. However, even the upgraded estimates could prove conservative given that IXICO has increased revenue at a compound annual growth rate of 35 per cent over the past three financial years and continues to win new contracts ('Profiting from artificial intelligence', 28 October 2019). Indeed, the closing order book of £15.9m equates to 80 per cent of the combined revenue forecast for the next two financial years, thus providing a high level of visibility and materially de-risking earnings estimates. IXICO has announced five notable contract wins since August, all of which highlight the value of its core technology and ability to unlock insights on a broad range of neurological disorders and across the full spectrum of clinical development. Interestingly, one of the contracts is focused on a progressive supranuclear palsy (PSP) programme for a new client, ahead of patient enrolment. The 12-month contract, worth £400,000, is expected to lead to a larger programme of work in early 2020, highlighting how the expansion of its services into new therapeutic markets. Another new contract involves a study with an existing client that will see IXICO’s AI technology extended and deployed to several sites in mainland China. Importantly, the company is well funded to maintain its growth trajectory, ending the 2019 financial year with net funds of £7.26m (15.5p a share), a sum equating to 25 per cent of IXICO’s market capitalisation of £31.2m. Strip out net funds, and the company’s enterprise value of £24m equates to 25 times net profit estimates of £947,000 for the 2020/21 financial year. However, if as seems likely IXICO continues to win new contracts, then analysts will be forced again to push through yet more earnings upgrades so that multiple is likely to drop sharply in due course. Buy. We then have no material news for 2 months.... Today Simon says: Aim-traded IXICO (IXI:85p), a London-based company that uses proprietary artificial intelligence (AI) software algorithms to analyse images from brain scans, has delivered a 157 per cent share price gain since I spotted its potential last summer ('Alpha Company Research: Simon Thompson spies opportunity in cutting edge technology', 23 July 2019). The share price is up 25 per cent since my last article (‘Playing an earnings upgrade cycle’, 12 December 2019), buoyed by news of a £1.8m extension to a Phase III study in Huntington's Disease, and a £0.6m extension to a study programme in Progressive Supranuclear Palsy. I really like the company and feel that if IXICO continues to win new contracts then analysts will be forced again to push through more earnings upgrades given the operational leverage of the business. However, as it stands right now, the shares trade on 32 times cash adjusted net profit estimates for the 2020/21 financial year and have hit my 85p target price. Take profits. Back to 68p - the same price as his "BUY" Tip last December. Surely he will shortly tell us what a Bargain it is again....
18/1/2020
18:09
geoff80: Directors love to be allotted options. Theoretically it is supposed to act as an incentive to reward them for any increase in the share price resulting from their successful management. Unfortunately for shareholders it is often a licence for Directors to print money particularly when options are sometimes granted already 'in the money' ie. already in profit. Directors in this case are rewarded if the share price does not fall. Unlike ordinary shareholders they have nothing to lose since options are free. So a win-win situation for them and a loss for shareholders' whose holdings are diluted if holders use their options to buy at the lower price. We all must regret not buying after seeing a big share price rise. Imagine being able to buy after the event at the price it was months or years ago. A no-brainer as they say.
29/10/2019
12:18
mirabeau: The contract momentum continues to build for Aim-traded IXICO (IXI:73p), a London-based company that uses proprietary artificial intelligence (AI) software algorithms to analyse images from brain scans – magnetic resonance imaging (MRI) and positron emission tomography (PET). Specifically, these scans provide measurements of small changes in brain structure, assess the efficacy of new drugs being trialled, monitor patient safety, and provide valuable insights on different aspects of trial performance. Having prompted analysts to materially upgrade their profit guidance not once, but twice since I first suggested buying the shares at 33p three months ago ('Alpha Report: Simon Thompson spies opportunity in cutting edge technology', 23 July 2019), IXICO has just announced three new biopharma contracts, all of which highlight the value of its core technology and ability to unlock insights on a broad range of neurological disorders and across the full spectrum of clinical development. The first contract is focused on a Progressive Supranuclear Palsy (PSP) programme for a new client, ahead of patient enrolment later in 2019. The 12-month contract, worth £400,000, is expected to lead to a larger programme of work in early 2020, according to IXICO’s directors. The second contract is worth £350,000 over three years and is an expansion of a study with an existing client which will see IXICO’s AI-technology extended and deployed to qualify several sites in mainland China. The third contract involves IXICO providing imaging analytics services to support a Phase IV programme in mental health for a new US-based biotechnology client. It’s worth £450,000 over the next two years. Alongside news of the contract awards, IXICO has announced the appointment of a chief business officer, Lammert Albers. His commercial experience in clinical research organisations includes roles at US$6.5bn market capitalisation Nasdaq-listed corporation, PRA Health Sciences (PRAH), and latterly with Australian Stock Exchange quoted CogState (COG), during which time he has developed deep expertise of the Alzheimer's disease (AD) trials market. Based in the US, Mr Albers will have responsibility for global business development, with a particular focus in driving international growth in North America & Asia. It’s a sound strategic move which supports IXICO’s strategy of growth through international expansion. True, the shares have now increased in value by 118 per cent on an offer-to-bid basis since I initiated coverage 13 weeks ago, and are within pennies of hitting the upgraded 75p target price I outlined a fortnight ago (‘IXICO upgrades guidance again’, 15 October 2019). But with contract momentum building strongly, and profits from a relatively fixed cost base highly operationally geared to rising sales, then I see ample scope for outperformance against analyst estimates which conservatively suggest operating profits of £941,000 on revenue of £10.9m in the 2020/21 financial year. Moreover, the company’s net cash of £7.3m (15.5p a share) equates to 22 per cent of IXICO’s market capitalisation of £33.3m, so the business has substantial funding in place to support further contract wins. The earnings upgrade cycle looks to have some way to run and I am tweaking my target up from 75p to 85p. Trading on a bid-offer spread of 72p to 73p, I continue to rate IXICO’s shares a buy.
20/8/2019
13:00
mirabeau: With a market capitalisation of £22m, Aim-traded IXICO (IXI:47p) may be under the radar of most investors, but the London-based company is at the forefront of a technological revolution. That’s because the world’s largest biopharmaceutical companies are investing huge sums of money in the field of neurology to target therapies for diseases affecting the central nervous system including Huntington’s, Alzeihmer’s and Parkinson’s disease. This has created a surge in demand for the services of companies that use proprietary artificial intelligence (AI) software algorithms to analyse images from brain scans - magnetic resonance imaging (MRI) and positron emission tomography (PET) – in order to provide measurements of small changes in brain structure, assess the efficacy of new drugs being trialled, monitor patient safety, and provide valuable insights on different aspects of trial performance. In a nut shell, IXICO’s cutting edge proprietary LEAP algorithm harnesses the power of large datasets and computer-based learning to segment specific regions of the brain and then accurately measure their volume, thus providing a reliable method of measuring brain atrophy which can indicate progression of neurological disease. To date the algorithm has been applied to over 150 brain regions, analysed over 100,000 brain scans and has been cited in over 750 scientific publications. The company has also developed AI technology to assess brain pathology like white matter lesions and, more recently, uses data from wearable biosensors to accurately measure sleep patterns in Parkinson’s disease and dementia patients. These approaches enhance the understanding of disease symptoms more directly compared to manual assessment or complex in-clinic technology. Importantly, by applying IXICO’s data science expertise, these measurements have the potential to increase success rates of clients’ clinical trials by improving patient selection, lowering the cost of running them, and reducing the burden on trial participants and their carers by reducing the need for clinic visits. High operational leverage The technology is proving incredibly popular. In fact, no fewer than eight of the 14 top 20 biopharmaceutical companies that have active neurological drug development programmes are clients of IXICO. They clearly hold the company in high esteem as IXICO has booked over £20m worth of new orders since the start of last year, a revenue stream that supports a sustained move to operating profitability. Once that inflexion point is passed, the high gross margin (62 per cent) earned from its cutting edge data analytics activities means that operating profits are set to move sharply higher in the years ahead given the significant amount of automation in the workflow and remote management of the clinical trial imaging sites. This means that IXICO is able to take on additional revenue generating activities without an equivalent increase in staffing costs, the effect of which is that any outperformance against revenue forecasts delivers a high conversion rate of incremental gross margin earned to operating profit. This operational leverage effect is also illustrated by the fact that over the past few years IXICO’s staffing levels have remained between 60 to 70 employees even though revenues earned have more than doubled since 2016. The possibility of profit upgrades was certainly not priced into the company’s valuation when I suggested buying IXICO’s shares, at 33p, in last month’s 8,000 word small-cap report for our Alpha subscribers ('Alpha: Simon Thompson spies opportunity in cutting edge technology', 23 July 2019). It still isn’t for that matter even after the 42 per cent rise in the company’s share price following yesterday’s trading update when management revealed that growth has been accelerated by new and existing contracts coming on line, deployment of newly developed algorithms and faster turnaround times in trial situations. Increased target price To put the current valuation into perspective, analyst Chris Donnellan at house broker Cenkos Securities has torn up his previous estimates and now expects IXICO to post 32 per cent revenue growth in the 2018/19 financial year, and 20 per cent top-line growth in both the 2019/20 and 2020/21 financial years, too. On this basis, IXICO’s annual pre-tax loss is forecast to be slashed from £0.8m to £0.1m on revenue up from £5.4m to £7.1m in the 12 months to 30 September 2019. Furthermore, Mr Donnellan now forecasts that IXICO will generate both an operating and pre-tax profit of £239,000 on revenue of £8.5m in the 2019/20 financial year to produce a net profit of £339,000, rising to an operating and pre-tax profit of £0.88m, and net profit of £0.79m on revenue of £10.25m in the 2020/21 financial year. He had previously forecast a £0.44m operating profit on revenues of £9.55m in the 2020/21 financial year, so the additional £0.7m of revenue that is now expected to be booked that year will produce £0.43m of incremental gross margin, all of which is effectively being converted into operating profit. Cenkos estimate IXICO will have net funds of £5.5m at the end of next month which means that its enterprise valuation of £16.5m equates to 20 times forecast net profits in the 2020/21 financial year, hardly a punchy rating for a highly operationally geared business that is winning new orders and looks to be at the start of an earnings upgrade cycle. Indeed, around two-thirds of the 2020 revenue target is already covered by the contracted order book, so if contract momentum continues to build then it’s not unrealistic to expect IXICO to over deliver even against analysts’ upgraded expectations. In the circumstances, I am raising my 55p target price to 62p, implying a fair value enterprise valuation of £23.5m, in anticipation of the contract momentum in the business continuing to build and the release of another positive pre-close trading update in mid-October. Trading on a bid-offer spread of 45p to 47p, I continue to rate IXICO’s shares a buy.
11/9/2018
07:22
jpuff: IXICO plc Contract with top 10 global pharmaceutical companySource: UK Regulatory (RNS & others)TIDMIXIRNS Number : 3166AIXICO plc11 September 201811 September 2018IXICO plc("IXICO" or the "Company")Significant new contract with a top 10 global pharmaceutical company to provide specialist medical imaging services for a Phase III Huntington's disease clinical trialHighlights the value of IXICO's data science expertise in neuroscience drug development.IXICO plc (AIM: IXI), the data science company delivering insights in neuroscience, today announced that it has signed a new contract with a top 10 global pharmaceutical company, to provide its technology enabled imaging services in support of a Pivotal Phase III study in Huntington's disease. The contract value of GBP9.1m will be delivered over a four year term.As part of this study, IXICO will utilise its expertise to optimise, standardise and collect magnetic resonance imaging (MRI) data from specialist imaging centres across North America, Latin America, Europe, Asia and Australasia. IXICO's data science expertise and artificial intelligence (AI) software algorithms will be applied to provide insights into brain cellular microstructure and neuronal connectivity to support the evaluation of drug safety and efficacy.This contract expands IXICO's relationship with an existing client and is the fourth new contract in Huntington's disease announced this financial year. It demonstrates the increasing adoption of IXICO's scientific and operational expertise in this important area of clinical development; Huntington's disease is a rare genetic neurodegenerative disorder which affects movement, cognition and behaviour.Giulio Cerroni, CEO of IXICO, said: "I am delighted to announce this new contract for a Pivotal Phase III clinical trial with an existing client which demonstrates confidence in IXICO's services to deliver valuable insights through our proprietary data analytics platform. Huntington's disease is an area of significant unmet medical need as there are currently no effective marketed treatments. This latest contract award reflects our experience working in this important area of neuroscience drug development which, together with previously announced new contracts and contract extensions, provides a strong foundation for future growth."For further information please contact: IXICO plc Giulio Cerroni, Chief Executive Officer Tel: +44 20 3763 7499 Susan Lowther, Chief Financial Officer Shore Capital (Nomad and Broker) Tel: +44 20 7408 4090 Edward Mansfield / Anita Ghanekar / Daniel Bush FTI Consulting Limited (Investor Relations) Tel: +44 20 3727 1000 Simon Conway/Mo Noonan About IXICOIXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our clients' neurodegenerative therapeutic pipeline through the application of advanced medical imaging and digital health technologies.IXICO's specialist data analytics services are used by the global pharmaceutical industry to analyse brain scan data and digital biomarkers to measure disease status and progression, enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical trial process evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDCNTEALNEFAAPEFF(END) Dow Jones NewswiresSeptember 11, 2018 02:00 ET (06:00 GMT)
16/11/2016
17:12
geoff80: LSE:IXI OKSearch Ixico Share News (IXI) 5 Follow IXI Share Name Share Symbol Market Type Share ISIN Share Description Ixico LSE:IXI London Ordinary Share GB00BCLY7L40 ORD 1P Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade +0.50p +2.04% 25.00p 24.00p 26.00p 25.00p 24.50p 24.50p 7,318 10:06:15 Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m) Pharmaceuticals & Biotechnology 3.1 -1.4 -7.9 - 6.62 Print Alert IXICO plc Participation in major EU partnership (ROADMAP) 16/11/2016 7:00am UK Regulatory (RNS & others) IXICO plc 16 November 2016 16(th) November 2016 IXICO plc ("IXICO" or the "Company") IXICO to receive EUR100k funding to provide digital technologies for collection and analysis of data in a "real world" setting Further expansion of work on wearable bio-sensors as part of a major EU public-private partnership (ROADMAP) IXICO, the brain health company, today announces its participation in a new collaborative pan-European research effort under the Innovative Medicines Initiative's (IMI) umbrella focused on addressing the challenges of successfully delivering therapies to people with Alzheimer's disease (AD). In this collaboration with leading pharmaceutical companies and academics, IXICO is receiving EUR100k of funding to undertake data aggregation and analysis using its digital technology platforms. The platforms will be used to devise clinically meaningful measurements from biosensors worn by patients, and to develop enhanced models of disease progression to help select the most appropriate treatment for an individual patient. Within ROADMAP, IXICO will demonstrate how both approaches can be deployed in real-world settings, leveraging IXICO's existing activities in the Cygnus real world evidence (RWE) study (hxxp://www.ixico.com/news/2016/06/ixico-cygnus-joins-DPUK). Derek Hill, CEO of IXICO, said: "IXICO is delighted to be joining the ROADMAP consortium. It provides an excellent opportunity for us to advance our capabilities in wearable biosensors and digital disease models, working collaboratively with leading pharmaceutical companies and academics. These are key technologies that are likely to accelerate the approval of and access to beneficial treatments for AD, and we believe they will provide commercial growth opportunities for IXICO." This project will enhance capabilities currently integrated into IXICO's TrialTracker(TM) and Assessa(R) digital health platforms, which are used by pharmaceutical companies both to support development of new treatments and used alongside marketed drugs. This innovative collaboration brings together 22 leading academic, healthcare and pharmaceutical partners, including Novartis Pharma AG, Eli Lilly and Company Ltd, Biogen, F. Hoffman-La Roche Ltd, Janssen Pharmaceutica NV, GE Healthcare Ltd and AC Immune SA. ROADMAP is also looking to identify which combinations of clinical tests and biomarkers support accurate diagnosis and prognosis of disease in asymptomatic patient populations in Alzheimer's disease. For further information please contact: IXICO plc Derek Hill, Chief Executive Officer Tel: +44 20 Susan Lowther, Chief Financial Officer 3763 7499 Shore Capital (Nomad and Broker) Tel: +44 20 Bidhi Bhoma / Edward Mansfield 7408 4090 FTI Consulting Limited (Investor Tel: +44 20 Relations) 3727 1000 Simon Conway/Mo Noonan/Matthew Moss About IXICO IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes. The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health. More information is available on www.ixico.com About ROADMAP ROADMAP aims to provide the foundation for a much-needed integrated data environment and framework for Real World Evidence (RWE) in AD including: -- The development of consensual key outcome measures across stakeholder groups; -- Enabling data integration tools for dataset characterisation and outcome classification, data standards, data sourcing, software application repository; -- Guidelines on the handling and interpretation of RWE data. In addition, the following priorities have been identified: -- Outcome measurement; -- Identifying the best natural history model; -- Identifying the best pharmacoeconomic modelling strategy; -- Using short-term data to model long-term effects; -- Using short-term data to model long-term economic impact; -- Association between cognition, QoL (quality of life) and function over the AD spectrum; -- Identifying combination markers for diagnosis in asymptomatic patient population; -- Identifying combination markers for prognosis. ROADMAP is mainly sponsored by the European Union's Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative 2 Joint Undertaking. The ROADMAP programme has budget of EUR7.77M distributed across a total of 22 partners from the private and academic sectors: * The University of Oxford * London School of Economics and Political Science * National Institute for Health and Care Excellence * Agentschap College ter Beoordeling van Geneesmiddelen * Erasmus Universitair Medisch Centrum Rotterdam * IXICO Technologies Ltd * Universiteit Maastricht * Rijksuniversiteit Groningen * Synapse Research Management Partners S.L. * Novartis Pharma AG (Project Leader) * Fundació Institut Universitari per la Recerca a * Eli Lilly and Company Ltd l'Atenció Primària de Salut Jordi Gol i Gurina * Biogen * Københavns Universitet * F. Hoffman-La Roche Ltd * Alzheimer Europe * Janssen Pharmaceutica NV * The University of Edinburgh * GE Healthcare Ltd * Goeteborgs Universitet * AC Immune SA * Aarhus Universitet About the Innovative Medicines Initiative The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA. More information can be found at www.imi.europa.eu Acknowledgement The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020. This
Ixico share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
IXI
Ixico
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201020 12:34:57